Executive Summary
HER2-selective, EGFR-sparing TKI designed for superior CNS penetration and tolerability in HER2+ cancers
Key Differentiators
- T-DXd has 30% serious AEs including ILD risk
- Zongertinib may have suboptimal CNS penetration
- Other HER2 TKIs have variable EGFR inhibition causing rash/diarrhea
NVL-330
HER2 · kinase inhibitor
Target: HER2
Full NameHuman Epidermal Growth Factor Receptor 2 (ERBB2)
PathwayHER2 mutation/amplification → constitutive signaling → tumor growth
Mechanism of Action
Indications: HER2+ NSCLCHER2+ solid tumors
Target Biology
HER2 is a receptor tyrosine kinase that when mutated or amplified drives tumor growth in multiple cancers including NSCLC. HER2 exon 20 insertions and point mutations represent distinct oncogenic drivers requiring targeted therapy.
Clinical Data
HEROEX-1 (NCT06521554)
Phase 1a/1bDesign: BOIN dose-escalation
Study Populations
| Cohort | N | Description |
|---|---|---|
| Phase 1 | Enrolling | HER2 mutation or amplification solid tumors |
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Key Risks
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Early Phase 1 with no clinical efficacy data | — | |
| Established competition (T-DXd, zongertinib) | — | |
| Differentiation must be proven clinically | — |
Peak Sales Estimate:
TBD - depends on differentiation vs T-DXd and zongertinib
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Phase 1 dose escalation data | 2026-2027 | high | Safety, tolerability, and early efficacy signals | — |